World's Best Scientists 2026 revealed!

D-Index & Metrics

Microbiology

D-Index
82
Citations
25231
World Ranking
1055
National Ranking
26

Medicine

D-Index
83
Citations
25379
World Ranking
15602
National Ranking
651

P. Richard Harrigan publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where P. Richard Harrigan sits on this spectrum.

55–64 publications: 8 scientists 65–74 publications: 29 scientists 75–84 publications: 55 scientists 85–94 publications: 112 scientists 95–104 publications: 137 scientists 105–114 publications: 190 scientists 115–124 publications: 235 scientists 125–134 publications: 234 scientists 135–144 publications: 288 scientists 145–154 publications: 265 scientists 155–164 publications: 264 scientists 165–174 publications: 253 scientists 175–184 publications: 276 scientists 185–194 publications: 190 scientists 195–204 publications: 234 scientists 205–214 publications: 208 scientists 215–224 publications: 198 scientists 225–234 publications: 155 scientists 235–244 publications: 161 scientists 245–254 publications: 160 scientists 255–264 publications: 146 scientists 265–274 publications: 139 scientists 275–284 publications: 148 scientists 285–294 publications: 115 scientists 295–304 publications: 96 scientists 305–314 publications: 88 scientists 315–324 publications: 106 scientists 325–334 publications: 65 scientists 335–344 publications: 76 scientists 345–354 publications: 64 scientists 355–364 publications: 62 scientists 365–374 publications: 65 scientists 375–384 publications: 61 scientists 385–394 publications: 34 scientists 395–404 publications: 44 scientists 405–414 publications: 36 scientists 415–424 publications: 35 scientists 425–434 publications: 29 scientists 435–444 publications: 33 scientists 445–454 publications: 34 scientists 455–464 publications: 25 scientists 465–474 publications: 26 scientists 475–484 publications: 20 scientists 485–494 publications: 19 scientists 495–504 publications: 16 scientists 505–514 publications: 17 scientists 515–524 publications: 23 scientists 525–534 publications: 14 scientists 535–544 publications: 14 scientists 545–554 publications: 18 scientists 555–564 publications: 12 scientists 565–574 publications: 7 scientists 575–584 publications: 9 scientists 585–594 publications: 9 scientists 595–604 publications: 9 scientists 605–614 publications: 7 scientists 615–624 publications: 9 scientists 625–634 publications: 7 scientists 635–644 publications: 4 scientists 645–654 publications: 5 scientists 655–664 publications: 6 scientists 665–674 publications: 7 scientists 675–678 publications: 3 scientists 679+ publications: 99 scientists
55 publications 679+

This scientist: 304 publications — 78th percentile

78% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 679 publications or more.

P. Richard Harrigan D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where P. Richard Harrigan sits on this spectrum.

40 D-Index: 30 scientists 41 D-Index: 86 scientists 42 D-Index: 90 scientists 43 D-Index: 117 scientists 44 D-Index: 122 scientists 45 D-Index: 123 scientists 46 D-Index: 108 scientists 47 D-Index: 110 scientists 48 D-Index: 106 scientists 49 D-Index: 109 scientists 50 D-Index: 129 scientists 51 D-Index: 111 scientists 52 D-Index: 116 scientists 53 D-Index: 127 scientists 54 D-Index: 134 scientists 55 D-Index: 134 scientists 56 D-Index: 112 scientists 57 D-Index: 136 scientists 58 D-Index: 162 scientists 59 D-Index: 151 scientists 60 D-Index: 139 scientists 61 D-Index: 123 scientists 62 D-Index: 126 scientists 63 D-Index: 144 scientists 64 D-Index: 109 scientists 65 D-Index: 103 scientists 66 D-Index: 124 scientists 67 D-Index: 112 scientists 68 D-Index: 103 scientists 69 D-Index: 131 scientists 70 D-Index: 94 scientists 71 D-Index: 93 scientists 72 D-Index: 96 scientists 73 D-Index: 92 scientists 74 D-Index: 80 scientists 75 D-Index: 66 scientists 76 D-Index: 87 scientists 77 D-Index: 60 scientists 78 D-Index: 73 scientists 79 D-Index: 59 scientists 80 D-Index: 57 scientists 81 D-Index: 55 scientists 82 D-Index: 47 scientists 83 D-Index: 77 scientists 84 D-Index: 50 scientists 85 D-Index: 45 scientists 86 D-Index: 42 scientists 87 D-Index: 41 scientists 88 D-Index: 32 scientists 89 D-Index: 38 scientists 90 D-Index: 35 scientists 91 D-Index: 34 scientists 92 D-Index: 27 scientists 93 D-Index: 26 scientists 94 D-Index: 33 scientists 95 D-Index: 22 scientists 96 D-Index: 37 scientists 97 D-Index: 22 scientists 98 D-Index: 21 scientists 99 D-Index: 22 scientists 100 D-Index: 30 scientists 101 D-Index: 16 scientists 102 D-Index: 20 scientists 103 D-Index: 17 scientists 104 D-Index: 19 scientists 105 D-Index: 16 scientists 106 D-Index: 19 scientists 107 D-Index: 18 scientists 108 D-Index: 14 scientists 109 D-Index: 10 scientists 110 D-Index: 9 scientists 111 D-Index: 7 scientists 112 D-Index: 11 scientists 113 D-Index: 6 scientists 114 D-Index: 15 scientists 115 D-Index: 10 scientists 116 D-Index: 12 scientists 117 D-Index: 7 scientists 118 D-Index: 10 scientists 119 D-Index: 10 scientists 120 D-Index: 11 scientists 121 D-Index: 2 scientists 122 D-Index: 7 scientists 123 D-Index: 12 scientists 124 D-Index: 5 scientists 125 D-Index: 9 scientists 126 D-Index: 6 scientists 127+ D-Index: 95 scientists
40 D-Index 127+

This scientist: 82 D-Index — 81st percentile

81% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 127 D-Index or more.

Overview

P. Richard Harrigan is affiliated with the University of British Columbia in Canada. Their research primarily focuses on infectious diseases, with a strong emphasis on HIV/AIDS and related viral infections. The scientist's work spans various fields including medicine, immunology and microbiology, infectious diseases, virology, epidemiology, molecular biology, and hepatology.

Their research topics prominently include:

  • HIV Research and Treatment
  • HIV/AIDS Drug Development and Treatment
  • HIV/AIDS Research and Interventions
  • Hepatitis C Virus Research
  • Hepatitis B Virus Studies
  • Liver Disease Diagnosis and Treatment
  • HIV-Related Health Complications and Treatments

Harrigan has published extensively in key venues that focus on virology and infectious diseases. Frequent publication venues include:

  • Viruses
  • The Journal of Infectious Diseases
  • PLoS Pathogens
  • JHEP Reports
  • HIV Medicine

Some recent notable papers authored or co-authored by Harrigan include:

  • "Multi-Laboratory Comparison of Next-Generation to Sanger-Based Sequencing for HIV-1 Drug Resistance Genotyping," 2020, Viruses
  • "Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals," 2022, JHEP Reports
  • "Are We Ready for NGS HIV Drug Resistance Testing? The Second 'Winnipeg Consensus' Symposium," 2020, Viruses
  • "Hospitalization Rates and Causes Among Persons With HIV in the United States and Canada, 2005-2015," 2020, The Journal of Infectious Diseases
  • "Opening the door on entry inhibitors in HIV: Redefining the use of entry inhibitors in heavily treatment experienced and treatment-limited individuals living with HIV," 2022, HIV Medicine

Harrigan collaborates regularly with various scientists in the field. Frequent co-authors include:

  • Richard D. Moore
  • Keri N. Althoff
  • Michael A. Horberg
  • Mari M. Kitahata
  • Neil Parkin

Their publication record reflects a strong engagement with HIV drug resistance, epidemiology of HIV-related complications, and the interplay between HIV and hepatitis viruses. Harrigan's work supports advancing knowledge on treatment strategies and viral resistance monitoring through molecular techniques and next-generation sequencing approaches.

Best Publications

  • The major genetic determinants of HIV-1 control affect HLA class I peptide presentation

    Pereyra F;Jia X;McLaren Pj

  • Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study

    Julio S.G. Montaner;Julio S.G. Montaner;Julio S.G. Montaner;Viviane D. Lima;Viviane D. Lima;Rolando Barrios;Benita Yip

  • Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy

    BA Larder;SD Kemp;PR Harrigan

  • Changes in Mitochondrial DNA as a Marker of Nucleoside Toxicity in HIV-Infected Patients

    Hélène C F Côté;Zabrina L Brumme;Kevin J P Craib;Christopher S Alexander

  • The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic

    Julio S. G. Montaner;Robert Hogg;Evan Wood;Thomas Kerr

  • Predictors of HIV Drug-Resistance Mutations in a Large Antiretroviral-Naive Cohort Initiating Triple Antiretroviral Therapy

    P. Richard Harrigan;Robert S. Hogg;Winnie W. Y. Dong;Benita Yip

  • Adaptation of HIV-1 to human leukocyte antigen class I

    Y. Kawashima;K. Pfafferott;J. Frater;P. Matthews

  • Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L.

    Evan Wood;Robert S. Hogg;Benita Yip;P. Richard Harrigan

  • Expansion of HAART Coverage Is Associated with Sustained Decreases in HIV/AIDS Morbidity, Mortality and HIV Transmission: The “HIV Treatment as Prevention” Experience in a Canadian Setting

    Julio S.G. Montaner;Viviane D. Lima;P. Richard Harrigan;Lillian Lourenço

  • Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study

    Evan Wood;Thomas Kerr;Brandon D L Marshall;Kathy Li

  • Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration

    Rami Kantor;David A Katzenstein;Brad Efron;Ana Patricia Carvalho

  • Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness.

    David R Bangsberg;Edward P Acosta;Reena Gupta;David Guzman

  • Molecular and Clinical Epidemiology of CXCR4-Using HIV-1 in a Large Population of Antiretroviral-Naive Individuals

    Zabrina L. Brumme;Zabrina L. Brumme;James Goodrich;Howard B. Mayer;Chanson J. Brumme

  • Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy.

    Viviane D. Lima;Robert S. Hogg;P. Richard Harrigan;David Moore

  • The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey.

    Thomas D. Madden;P.Richard Harrigan;Linda C.L. Tai;Marcel B. Bally

  • Expanded Access to Highly Active Antiretroviral Therapy: A Potentially Powerful Strategy to Curb the Growth of the HIV Epidemic

    Viviane D. Lima;Karissa Johnston;Karissa Johnston;Robert S. Hogg;Adrian R. Levy;Adrian R. Levy

  • Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis

    Soo Yon Rhee;Jose Luis Blanco;Michael R. Jordan;Jonathan Taylor

  • Predictors of viral suppression and rebound among HIV-positive men who have sex with men in a large multi-site Canadian cohort

    Zachary Tanner;Nathan Lachowsky;Nathan Lachowsky;Erin Ding;Hasina Samji

  • Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring.

    J. Moodley;D. Moodley;K. Pillay;H. Coovadia

  • Relative Replicative Fitness of Zidovudine-Resistant Human Immunodeficiency Virus Type 1 Isolates In Vitro

    P. Richard Harrigan;Stuart Bloor;Brendan A. Larder

  • Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART.

    Robert S Hogg;Robert S Hogg;David R Bangsberg;Viviane D Lima;Chris Alexander

Frequent Co-Authors

Julio S. G. Montaner
Julio S. G. Montaner University of British Columbia
Robert S. Hogg
Robert S. Hogg Simon Fraser University
Zabrina L. Brumme
Zabrina L. Brumme Simon Fraser University
Chanson J. Brumme
Chanson J. Brumme University of British Columbia
Benita Yip
Benita Yip University of British Columbia
Viviane D. Lima
Viviane D. Lima University of British Columbia
Evan Wood
Evan Wood University of British Columbia
Mark A. Brockman
Mark A. Brockman Simon Fraser University
Jonathan M. Carlson
Jonathan M. Carlson Microsoft (United States)
David R. Bangsberg
David R. Bangsberg Simon Fraser University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Microbiology in the USA opens doors to a variety of related online degrees and career options. For individuals with diverse backgrounds, including those with past legal challenges, pursuing the best degrees for felons can provide a valuable second chance in education and professional growth.

One promising healthcare pathway connected to microbiology is becoming a functional medicine nurse. This role integrates scientific knowledge with holistic care, emphasizing patient-centered approaches in treatment plans.

Additionally, technical certifications such as the cpc certification can complement microbiology expertise by enabling careers in medical coding and healthcare administration. These skills are in high demand and offer strong job security.

For those interested in leadership positions, pursuing a master in health information management salary reflects the potential financial benefits and career growth opportunities available in managing healthcare data and compliance.

Best Scientists Citing P. Richard Harrigan

Trending Scientists

Recently Published Articles